Kura Oncology rises following Jim Cramer comments
Source: SeekingAlpha
2025-12-22 12:01:03 ET
More on Kura Oncology
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML - Slideshow
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
- Kura Oncology: A Cautious Buy
- Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
- Kura Oncology wins FDA approval for leukemia drug
Read the full article on Seeking Alpha
For further details see:
Kura Oncology rises following Jim Cramer comments
Kyowa Hakko Kogyo
NASDAQ: KYKOF
KYKOF Trading
-13.15% G/L:
$12.42 Last:
100 Volume:
$12.42 Open:
